University of Massachusetts Medical School Faculty Publications

UMMS Affiliation

Program in Molecular Medicine; Davis Lab

Publication Date

2019-09-05

Document Type

Article Postprint

Disciplines

Amino Acids, Peptides, and Proteins | Cell Biology | Cells | Cellular and Molecular Physiology | Digestive System | Digestive System Diseases | Hepatology | Hormones, Hormone Substitutes, and Hormone Antagonists | Nucleic Acids, Nucleotides, and Nucleosides

Abstract

SAB is an outer membrane docking protein for JNK mediated impaired mitochondrial function. Deletion of Sab in hepatocytes inhibits sustained JNK activation and cell death. Current work demonstrated that increasing SAB enhanced the severity of APAP liver injury. Female mice were resistant to liver injury and exhibited markedly decreased hepatic SAB protein expression versus males. The mechanism of SAB repression involved a pathway from ERalpha to p53 expression which induced miR34a-5p. miR34a-5p targeted the Sab mRNA coding region, repressing SAB expression. Fulvestrant or p53 knockdown decreased miR34a-5p and increased SAB in females leading to increased injury from APAP and TNF/galactosamine. In contrast, ERalpha agonist increased p53 and miR34a-5p which decreased SAB expression and hepatotoxicity in males. Hepatocyte-specific deletion of miR34a also increased severity of liver injury in females, which was prevented by GalNAc-ASO knockdown of Sab. Similar to mice, premenopausal human females also expressed high hepatic p53 and low SAB levels while age-matched males expressed low p53 and high SAB levels, but there was no sex difference of SAB expression in postmenopause. In conclusion, the level of SAB expression determined the severity of JNK dependent liver injury. Females expressed low hepatic SAB protein levels due to an ERalpha-p53-miR34a pathway which repressed SAB expression, accounting for resistance to liver injury.

Keywords

Apoptosis, Hepatology, P53, Sex hormones

Rights and Permissions

Copyright © 2019 American Society for Clinical Investigation. Final accepted manuscript posted as allowed by publisher's policy at https://www.jci.org/kiosks/terms.

DOI of Published Version

10.1172/JCI128289

Source

J Clin Invest. 2019 Sep 5. pii: 128289. doi: 10.1172/JCI128289. [Epub ahead of print] Link to article on publisher's site

Related Resources

Link to Article in PubMed

Journal/Book/Conference Title

The Journal of clinical investigation

PubMed ID

31487267

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.